A heroin overdose laboratory model: How do escalating doses of diamorphine alter respiratory function in a diamorphine-treated population?

IF 5.2 1区 医学 Q1 PSYCHIATRY Addiction Pub Date : 2025-02-10 DOI:10.1111/add.70005
Basak Tas, Nicola J Kalk, Edward Chesney, Rob van der Waal, Alastair Boyd, James Bell, Mike Kelleher, John Moxham, Will Lawn, Caroline J Jolley, John Strang
{"title":"A heroin overdose laboratory model: How do escalating doses of diamorphine alter respiratory function in a diamorphine-treated population?","authors":"Basak Tas, Nicola J Kalk, Edward Chesney, Rob van der Waal, Alastair Boyd, James Bell, Mike Kelleher, John Moxham, Will Lawn, Caroline J Jolley, John Strang","doi":"10.1111/add.70005","DOIUrl":null,"url":null,"abstract":"<p><strong>Background & aim: </strong>Globally, more than 100 000 people die annually from opioid overdose. Although strongly implicated in heroin overdose deaths, acute opioid-induced respiratory depression is poorly understood, and few laboratory studies have been completed in human subjects. It is an area of undone science. Using a human laboratory overdose model, our research question was: what is the strength of the association between increasing dose of diamorphine and degree of respiratory depression in people prescribed injectable diamorphine for heroin use disorder?</p><p><strong>Design: </strong>Single-blind, Phase IV, non-randomised, dose-escalation clinical trial.</p><p><strong>Setting: </strong>King's Clinical Research Facility, London, UK.</p><p><strong>Participants: </strong>Four participants prescribed injectable diamorphine as treatment for heroin use disorder [all male, median (range) age 63 (59-72)].</p><p><strong>Interventions: </strong>The following dosing schedule was implemented (as a % of participant's usual prescribed diamorphine dose): visit 1-100%; visit 2-110%; visit 3-120%; visit 4-100%. Usual dose: 97.5 mg (30 mg-200 mg).</p><p><strong>Measurements: </strong>Physiological measures included: pulse oximetry (SpO<sub>2</sub>%), end-tidal CO<sub>2</sub> (ETCO<sub>2</sub>%), transcutaneous CO<sub>2</sub>, respiratory rate and parasternal electromyography to measure neural respiratory drive index (NRDI). Recordings were made continuously from 3 mins pre-dose to 60 mins post-dose.</p><p><strong>Findings: </strong>Respiratory measures from baseline to post-dose across all dose sessions had ranges of: 89.7%-99.5% SpO<sub>2</sub>%; 4.8%-7.7% ETCO<sub>2</sub>%; 5.2-13.4 breaths/minute respiratory rate; 51.2 min<sup>-1</sup>-165.9 min<sup>-1</sup> NRDI across all participants. All diamorphine doses caused some reduction in respiratory function. There was no clear difference between diamorphine dose and the degree of respiratory depression, based on descriptive analyses.</p><p><strong>Conclusions: </strong>A dose-escalation clinical trial of people prescribed injectable diamorphine for heroin addiction found that the degree of respiratory depression caused by diamorphine does not appear to be dose dependent; however, the changes seen at diamorphine doses to which participants were accustomed suggest that participants had only partial tolerance to the respiratory depressant effect of diamorphine.</p>","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":""},"PeriodicalIF":5.2000,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Addiction","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/add.70005","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

Abstract

Background & aim: Globally, more than 100 000 people die annually from opioid overdose. Although strongly implicated in heroin overdose deaths, acute opioid-induced respiratory depression is poorly understood, and few laboratory studies have been completed in human subjects. It is an area of undone science. Using a human laboratory overdose model, our research question was: what is the strength of the association between increasing dose of diamorphine and degree of respiratory depression in people prescribed injectable diamorphine for heroin use disorder?

Design: Single-blind, Phase IV, non-randomised, dose-escalation clinical trial.

Setting: King's Clinical Research Facility, London, UK.

Participants: Four participants prescribed injectable diamorphine as treatment for heroin use disorder [all male, median (range) age 63 (59-72)].

Interventions: The following dosing schedule was implemented (as a % of participant's usual prescribed diamorphine dose): visit 1-100%; visit 2-110%; visit 3-120%; visit 4-100%. Usual dose: 97.5 mg (30 mg-200 mg).

Measurements: Physiological measures included: pulse oximetry (SpO2%), end-tidal CO2 (ETCO2%), transcutaneous CO2, respiratory rate and parasternal electromyography to measure neural respiratory drive index (NRDI). Recordings were made continuously from 3 mins pre-dose to 60 mins post-dose.

Findings: Respiratory measures from baseline to post-dose across all dose sessions had ranges of: 89.7%-99.5% SpO2%; 4.8%-7.7% ETCO2%; 5.2-13.4 breaths/minute respiratory rate; 51.2 min-1-165.9 min-1 NRDI across all participants. All diamorphine doses caused some reduction in respiratory function. There was no clear difference between diamorphine dose and the degree of respiratory depression, based on descriptive analyses.

Conclusions: A dose-escalation clinical trial of people prescribed injectable diamorphine for heroin addiction found that the degree of respiratory depression caused by diamorphine does not appear to be dose dependent; however, the changes seen at diamorphine doses to which participants were accustomed suggest that participants had only partial tolerance to the respiratory depressant effect of diamorphine.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
Addiction
Addiction 医学-精神病学
CiteScore
10.80
自引率
6.70%
发文量
319
审稿时长
3 months
期刊介绍: Addiction publishes peer-reviewed research reports on pharmacological and behavioural addictions, bringing together research conducted within many different disciplines. Its goal is to serve international and interdisciplinary scientific and clinical communication, to strengthen links between science and policy, and to stimulate and enhance the quality of debate. We seek submissions that are not only technically competent but are also original and contain information or ideas of fresh interest to our international readership. We seek to serve low- and middle-income (LAMI) countries as well as more economically developed countries. Addiction’s scope spans human experimental, epidemiological, social science, historical, clinical and policy research relating to addiction, primarily but not exclusively in the areas of psychoactive substance use and/or gambling. In addition to original research, the journal features editorials, commentaries, reviews, letters, and book reviews.
期刊最新文献
Deficits in general and smoking-specific response inhibition in the Go/No-Go task in individuals who smoke: A cross-sectional analysis. Efficacy of cannabidiol alone or in combination with Δ-9-tetrahydrocannabinol for the management of substance use disorders: An umbrella review of the evidence. High BMI is a specific risk factor for drug-related mortality in patients receiving methadone: A case control study. Issue Information Issue Information
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1